KIF11 and gastric adenocarcinoma: To conclude it can be argued that our novel Eg5 inhibitors in monotherapy are able to counteract gastric adenocarcinoma cells proliferation and invasiveness, moreover, the synergistic effect, enhanced by the combination therapy with K858 could be a promising strategy to induce cell death through the apoptotic cascade activation.